💥 Gate Square Event: #PostToWinPORTALS# 💥
Post original content on Gate Square related to PORTALS, the Alpha Trading Competition, the Airdrop Campaign, or Launchpool, and get a chance to share 1,300 PORTALS rewards!
📅 Event Period: Sept 18, 2025, 18:00 – Sept 25, 2025, 24:00 (UTC+8)
📌 Related Campaigns:
Alpha Trading Competition: Join for a chance to win rewards
👉 https://www.gate.com/announcements/article/47181
Airdrop Campaign: Claim your PORTALS airdrop
👉 https://www.gate.com/announcements/article/47168
Launchpool: Stake GT to earn PORTALS
👉 https://www.gate.com/announcements/articl
BioNTech rose about 8.5% after reaching a licensing protocol worth over $11 billion with Bristol-Myers Squibb.
Golden Ten Data reported on June 3 that BioNTech SE (BNTX.O) continued to rise about 8.5% to $122.7. The stock rose more than 18% yesterday. On the news side, Squibb announced that it has reached a licensing agreement with BioNTech for a new generation of anti-cancer drug BNT327, with milestone payments of up to $11.1 billion. Truist Securities raised its price target on BioNTech to $155 from $151, maintaining a "buy" rating.